N-type calcium channels and their regulation by GABAB receptors in axons of neonatal rat optic nerve.
Axons of neonatal rat optic nerves exhibit fast calcium transients in response to brief action potential stimulation. In response to one to four closely spaced action potentials, evoked calcium transients showed a fast-rising phase followed by a decay with a time constant of approximately 2-3 sec. By selective staining of axons or glial cells with calcium dyes, it was shown that the evoked calcium transient originated from axons. The calcium transient was caused by influx because it was eliminated when bath calcium was removed. Pharmacological profile studies with calcium channel subtype-specific peptides suggested that 58% of the evoked calcium influx was accounted for by N-type calcium channels, whereas L- and P/Q-type calcium channels had little, if any, contribution. The identity of the residual calcium influx remains unclear. GABA application caused a dramatic reduction of the amplitude of the action potential and the associated calcium influx. When GABAA receptors were blocked by bicuculline, the inhibitory effect of GABA on the action potential was eliminated, whereas that on the calcium influx was not, indicating involvement of GABAB receptors. Indeed, the calcium influx was inhibited by the GABAB receptor agonist baclofen. This baclofen effect was occluded by a previous block of N-type calcium channels and was unaffected by the broad-spectrum K+ channel blocker 4-AP. We conclude that neonatal rat optic nerve axons express N-type calcium channels, which are subjected to regulation by G-protein-coupled GABAB receptors. We suggest that receptor-mediated inhibition of axonal calcium channels plays a protective role in neonatal anoxic and/or ischemic injury.
Sun
B B
BB
Graduate Program in Biophysics, University of Wisconsin School of Medicine, Madison, Wisconsin 53706, USA.
Chiu
S Y
SY
D000200:Action Potentials / Q000187:drug effects; D000241:Adenosine / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001369:Axons / Q000187:drug effects / Q000378:metabolism*; D001418:Baclofen / Q000037:antagonists & inhibitors / Q000494:pharmacology; D001640:Bicuculline / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000378:metabolism*; D002413:Cations, Divalent / Q000494:pharmacology; D018682:GABA Agents / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000502:physiology; D066298:In Vitro Techniques; D009457:Neuroglia / Q000378:metabolism; D009900:Optic Nerve / Q000187:drug effects / Q000378:metabolism*; D026902:Potassium Channel Blockers; D051381:Rats; D017207:Rats, Sprague-Dawley; D018080:Receptors, GABA-B / Q000502:physiology*; D019831:Sodium-Calcium Exchanger / Q000037:antagonists & inhibitors / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D002413:Cations, Divalent; D018682:GABA Agents; D026902:Potassium Channel Blockers; D018080:Receptors, GABA-B; D019831:Sodium-Calcium Exchanger; D005680:gamma-Aminobutyric Acid; D019204:GTP-Binding Proteins; D001418:Baclofen; D000241:Adenosine; D002118:Calcium; D001640:Bicuculline